Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 5;21(1):10.
doi: 10.1186/s12885-020-07710-7.

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

J Smith-Palmer  1 , O R Leeuwenkamp  2 , J Virk  3 , N Reed  4
Affiliations

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

J Smith-Palmer et al. BMC Cancer. .

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with 177Lu-Dotatate resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with best supportive care (BSC) with high dose octreotide long-acting repeatable (LAR) 60 mg. A health economic analysis was performed using input data from clinical studies and data derived from an indirect comparison to determine the cost-effectiveness of 177Lu-Dotatate in the treatment of GI-NETs and pancreatic NETs (P-NETs) in Scotland.

Methods: Cost-effectiveness analysis was performed from the payer perspective using a three-state partitioned survival model. In the base case 177Lu-Dotatate was compared with BSC in gastrointestinal (GI)-NETs using clinical data from the NETTER-1 trial. A secondary analysis comparing 177Lu-Dotatate with BSC, everolimus or sunitinib in patients with P-NETs was also performed using hazard ratios inferred from indirect comparisons. The base case analysis was performed over a 20-year time horizon with an annual discount rate of 3.5% for both costs and clinical outcomes.

Results: For unresectable/metastatic progressive GI-NETs treatment with 177Lu-Dotatate led to a gain in quality-adjusted life expectancy of 1.33 quality-adjusted life years (QALYs) compared with BSC due to extended PFS and OS. Mean total lifetime costs were GBP 35,701 higher with 177Lu-Dotatate, leading to an incremental cost-effectiveness ratio (ICER) of GBP 26,830 per QALY gained. In analyses in patients with P-NETs 177Lu-Dotatate was associated with ICERs below GBP 30,000 per QALY gained in comparisons with BSC, sunitinib and everolimus.

Conclusions: Cost-effectiveness analyses demonstrated that, in Scotland, from the payer perspective, 177Lu-Dotatate at the set acquisition cost is a cost-effective treatment option for patients with unresectable or metastatic progressive GI-NETs or P-NETs.

Keywords: Cost; Cost-effectiveness; Gastroenteropancreatic neuroendocrine tumors; Radionuclides; Scotland.

PubMed Disclaimer

Conflict of interest statement

OL and JV are current employees of AAA, which manufactures Lutathera. JSP is a current employee of Ossian Health Economics and Communications, which has received consulting fees from AAA. NR has received honoraria/consulting fees from Novartis/AAA, which manufactures Lutathera as well as Roche, Esai and Ipsen.

Figures

Fig. 1
Fig. 1
Schematic diagram of partitioned survival model used in the analysis
See this image and copyright information in PMC

References

    1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991–1002. - PMC - PubMed
    1. Fraenkel M, Faggiano A, Valk GD. Epidemiology of Neuroendocrine Tumors. Front Horm Res. 2015;44:1–23. - PubMed
    1. National Cancer Registration and Analysis Service. Incidence and survival in neuroendocrine tumours and neuroendocrine carcinomas (NETs/NECs) in England, 2013–2014. Available at: www.ncin.org.uk/view?rid=3268 [Last Accessed 07 Aug 2019].
    1. Genus TSE, Bouvier C, Wong KF, Srirajaskanthan R, Rous BA, Talbot DC, Valle JW, Khan M, Pearce N, Elshafie M, Reed NS, Morgan E, Deas A, White C, Huws D, Ramage J. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015. Br J Cancer. 2019. 10.1038/s41416-019-0606-3 [Epub ahead of print]. - PMC - PubMed
    1. UK Office for National Statistics. Scotland population mid-year estimates. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigrati... [Last Accessed 06 Aug 2019].

MeSH terms

Supplementary concepts